再鼎医药 港股通 空最新增减持 (2026-07-02) 官网 ( 09688.hk) | -12.60 | 3.37 | 0% | 上市时间2020-09-28股价15.38港币涨跌幅-4.05%成交金额7,282.70万港币换手率0.42%市值175.00亿港币H股市值175.00亿港币总股本11.38亿H股本11.38亿每手股数100上市至今年化投资收益率-21.51%港股通持仓占H股比例37.31% (67.59亿港币2026-07-21) 累计做空占H股比例12.68% (22.36亿港币2026-07-17) | |||
| 所属三级行业生物技术 (恒生) | 市盈率 | 122.29 | 市净率 | 4.46 | 股息率 | 0.37% | 恒生:医疗保健业药品及生物科技生物技术 |
| 所属指数指数纳入纳出 | |||||||
| 备注 (5): | 双击编辑备注 |
再鼎医药(09688) - 历史董事名单
| # | 姓名 | 职衔 | 职位 | 委任日期 | 辞任日期 |
|---|---|---|---|---|---|
| 1 | VOUNATSOS Michel Pericles | Independent Non Executive Director | 2023-01-09 | -- | |
| 2 | GAYNOR Richard Brian | Independent Non Executive Director | 2021-11-19 | -- | |
| 3 | MORRISON Scott William | Independent Non Executive Director | 2021-10-13 | -- | |
| 4 | 梁頴宇 | Independent Non Executive Director | 2020-07-01 | -- | |
| 5 | MOULDER JR Leon Oliver | Independent Non Executive Director | 2020-01-01 | -- | |
| 6 | LIS William David | Independent Non Executive Director | 2018-10-01 | -- | |
| 7 | 陳凱先 | Independent Non Executive Director | 2018-08-01 | -- | |
| 8 | DIEKMAN John David | Independent Non Executive Director | 2017-08-01 | -- | |
| 9 | 傅濤 | Executive Director | 2017-08-01 | 2021-05-07 | |
| 10 | WIRTH Peter Karl | Independent Non Executive Director | 2017-06-01 | -- | |
| 11 | 杜瑩 | Executive Director | Chairman, CEO | 2013-03-01 | -- |